EP1119375A4 - Methods and adjuvants for stimulating mucosal immunity - Google Patents

Methods and adjuvants for stimulating mucosal immunity

Info

Publication number
EP1119375A4
EP1119375A4 EP99949664A EP99949664A EP1119375A4 EP 1119375 A4 EP1119375 A4 EP 1119375A4 EP 99949664 A EP99949664 A EP 99949664A EP 99949664 A EP99949664 A EP 99949664A EP 1119375 A4 EP1119375 A4 EP 1119375A4
Authority
EP
European Patent Office
Prior art keywords
adjuvants
methods
mucosal immunity
stimulating mucosal
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99949664A
Other languages
German (de)
French (fr)
Other versions
EP1119375A1 (en
Inventor
Eyal Raz
Anthony A Horner
Dennis A Carson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1119375A1 publication Critical patent/EP1119375A1/en
Publication of EP1119375A4 publication Critical patent/EP1119375A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
EP99949664A 1998-10-05 1999-09-15 Methods and adjuvants for stimulating mucosal immunity Withdrawn EP1119375A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US167039 1988-03-11
US16703998A 1998-10-05 1998-10-05
PCT/US1999/021203 WO2000020039A1 (en) 1998-10-05 1999-09-15 Methods and adjuvants for stimulating mucosal immunity

Publications (2)

Publication Number Publication Date
EP1119375A1 EP1119375A1 (en) 2001-08-01
EP1119375A4 true EP1119375A4 (en) 2005-02-02

Family

ID=22605695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99949664A Withdrawn EP1119375A4 (en) 1998-10-05 1999-09-15 Methods and adjuvants for stimulating mucosal immunity

Country Status (5)

Country Link
EP (1) EP1119375A4 (en)
JP (1) JP2002526425A (en)
AU (1) AU776288B2 (en)
CA (1) CA2346452A1 (en)
WO (1) WO2000020039A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001055341A2 (en) 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
AU2001249609A1 (en) 2000-03-28 2001-10-08 Department Of Veterans Affairs Methods for increasing a cytotoxic T lymphocyte response in vivo
WO2002088081A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
CA2504493C (en) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CA2527756C (en) 2003-05-15 2014-05-06 Japan Science And Technology Agency Immunostimulating agents
RU2390351C2 (en) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Mucosal influenza virus vaccine and method for influenza prevention
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP5028627B2 (en) 2005-08-05 2012-09-19 国立大学法人徳島大学 Antigen drug vehicle that enables switching from selective production of IgA antibody to production of both IgA and IgG antibodies, and nasal / mucosal vaccine using the same
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
IL296071A (en) * 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930893B1 (en) * 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
ATE370740T1 (en) * 1997-05-20 2007-09-15 Ottawa Health Research Inst METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS
CA2302805A1 (en) * 1997-09-05 1999-03-11 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIS H L ET AL: "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JAN 1998, vol. 160, no. 2, 15 January 1998 (1998-01-15), pages 870 - 876, XP002109526, ISSN: 0022-1767 *
KRIEG ARTHUR M ET AL: "The role of CpG dinucleotides in DNA vaccines", TRENDS IN MICROBIOLOGY, vol. 6, no. 1, January 1998 (1998-01-01), pages 23 - 27, XP000857633, ISSN: 0966-842X *
See also references of WO0020039A1 *
WEINER GEORGE J ET AL: "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 20, 1997, pages 10833 - 10837, XP002120387, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2000020039A1 (en) 2000-04-13
EP1119375A1 (en) 2001-08-01
AU6249399A (en) 2000-04-26
CA2346452A1 (en) 2000-04-13
WO2000020039A9 (en) 2000-09-21
AU776288B2 (en) 2004-09-02
JP2002526425A (en) 2002-08-20

Similar Documents

Publication Publication Date Title
EP1119375A4 (en) Methods and adjuvants for stimulating mucosal immunity
AU2024500A (en) Intraoral electromuscular stimulation device and method
GB9812613D0 (en) Vaccine
GB9718901D0 (en) Vaccine
GB9727262D0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
HUP0105392A3 (en) Enhanced vaccines
GB9822714D0 (en) Vaccines
GB0027072D0 (en) Vaccine
GB9626864D0 (en) Vaccine
GB9611673D0 (en) Meningococcal vaccine
EP1064390A4 (en) Enhanced anti-tumor immunity
GB9718616D0 (en) Oral vaccine
GB9820956D0 (en) Vaccine
GB9821821D0 (en) Schistomiasis vaccine
GB9807805D0 (en) Vaccine
GB9809958D0 (en) Vaccine
GB9805962D0 (en) Vaccine
GB9802543D0 (en) Vaccine
GB9802544D0 (en) Vaccine
GB9807933D0 (en) Vaccine
GB9812228D0 (en) Vaccine
GB9822712D0 (en) Vaccine
GB9822709D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041221

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/39 B

Ipc: 7C 12N 15/00 B

Ipc: 7A 61K 48/00 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050331